Nutritional management of glycogen storage disease type III: a case report and a critical appraisal of the literature.

cardiomyopathy continuous glucose monitoring (CGM) dietary intervention glycogen storage disease high-fat diet myopathy

Journal

Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264

Informations de publication

Date de publication:
2023
Historique:
received: 02 03 2023
accepted: 13 04 2023
medline: 30 5 2023
pubmed: 30 5 2023
entrez: 30 5 2023
Statut: epublish

Résumé

Glycogen storage disease Type III (GSD III) is an autosomal recessive disease due to the deficiency of the debranching enzyme, which has two main consequences: a reduced availability of glucose due to the incomplete degradation of glycogen, and the accumulation of abnormal glycogen in liver and cardiac/skeletal muscle. The role of dietary lipid manipulations in the nutritional management of GSD III is still debated. A literature overview shows that low-carbohydrate (CHO) / high-fat diets may be beneficial in reducing muscle damage. We present a 24-year GSD IIIa patient with severe myopathy and cardiomyopathy in whom a gradual shift from a high-CHO diet (61% total energy intake), low-fat (18%), high-protein (21%) to a low-CHO (32 %) high-fat (45%) / high-protein (23%) diet was performed. CHO was mainly represented by high-fiber, low glycemic index food, and fat consisted prevalently of mono and polyunsaturated fatty acids. After a 2-year follow-up, all biomarkers of muscle and heart damage markedly decreased (by 50-75%), glucose levels remained within the normal range and lipid profile was unchanged. At echocardiography, there was an improvement in geometry and left ventricular function. A low -CHO, high-fat, high-protein diet seems to be safe, sustainable and effective in reducing muscle damage without worsening cardiometabolic profile in GSDIIIa. This dietary approach could be started as early as possible in GSD III displaying skeletal/cardiac muscle disease in order to prevent/minimize organ damage.

Identifiants

pubmed: 37252245
doi: 10.3389/fnut.2023.1178348
pmc: PMC10213733
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1178348

Informations de copyright

Copyright © 2023 Massimino, Amoroso, Lupoli, Rossi and Capaldo.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Neuromuscul Disord. 1999 Oct;9(6-7):408-10
pubmed: 10545045
Orphanet J Rare Dis. 2014 Nov 28;9:196
pubmed: 25431232
J Inherit Metab Dis. 2009 Dec;32 Suppl 1:S103-6
pubmed: 19322675
Mol Genet Metab Rep. 2022 Aug 01;32:100904
pubmed: 36046398
Mol Genet Metab Rep. 2020 Jul 16;24:100628
pubmed: 32714838
Pediatr Res. 2011 Dec;70(6):638-41
pubmed: 21857385
J Inherit Metab Dis. 2020 Jul;43(4):770-777
pubmed: 32064649
J Inherit Metab Dis. 1998 Feb;21(1):80-1
pubmed: 9501276
Lancet. 2003 Apr 26;361(9367):1433-5
pubmed: 12727399
J Inherit Metab Dis. 2015 May;38(3):537-43
pubmed: 25633903
Ann Nutr Metab. 2020;76(4):233-241
pubmed: 32712609
Ital J Pediatr. 2022 Mar 28;48(1):48
pubmed: 35346323
JIMD Rep. 2012;5:13-6
pubmed: 23430911
J Inherit Metab Dis. 2022 Nov;45(6):1018-1027
pubmed: 36088581
Mol Genet Metab Rep. 2021 Nov 11;29:100821
pubmed: 34820282
Hum Mol Genet. 2019 Oct 1;28(R1):R31-R41
pubmed: 31227835
J Am Coll Cardiol. 2021 Apr 6;77(13):1660-1669
pubmed: 33637354
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5566-5572
pubmed: 31322653
J Inherit Metab Dis. 2016 Sep;39(5):697-704
pubmed: 27106217
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3612-e3623
pubmed: 35786777
Acta Myol. 2019 Jun 01;38(1):17-20
pubmed: 31309177
Genet Med. 2010 Jul;12(7):446-63
pubmed: 20631546
Blood Cells Mol Dis. 2011 Jan 15;46(1):42-6
pubmed: 21075022
Ann Neurol. 1982 Apr;11(4):420-2
pubmed: 7049057
JIMD Rep. 2014;17:91-5
pubmed: 25308556
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825

Auteurs

Elena Massimino (E)

Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.

Anna Paola Amoroso (AP)

Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.

Roberta Lupoli (R)

Department of Molecular Medicine and Medical Biotechnology, University Federico II, Naples, Italy.

Alessandro Rossi (A)

Department of Translational Medicine, Section of Pediatrics, University Federico II, Naples, Italy.

Brunella Capaldo (B)

Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.

Classifications MeSH